Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages 50-60 years. RA is typically characterized by morning stiffness and symmetrical joint swelling of the feet, hands, and knees, although any joint (and in some cases, internal organs) may be involved. The course of RA may be complicated by cardiac, hematologic, and other extra-articular manifestations.
Interventions of Interest:
- Baricitinib (Olumiant®, Eli Lilly and Co.)
- Tofacitinib (Xeljanz®, Pfizer)
- Upadacitinib (Rinvoq™, AbbVie)
In addition to this list of drugs, ICER is considering investigating several biosimilars as part of the 2019 review.
*In June 2019, ICER refocused the review on JAK inhibitors only, as opposed to a full class review.
Below you will find the final documents from the policy paper review process: